Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ACTU
Stock Latest News
The Fly
Actuate Therapeutics price target lowered to $15 from $20 at H.C. Wainwright
2d ago
ACTU
Premium
The Fly
Actuate launches research initiative to combine elraglusib, RAS inhibitors
1M ago
ACTU
Premium
The Fly
Actuate Therapeutics announces plans to expand clinical pipeline
3M ago
ACTU
Premium
Company Announcements
Actuate Therapeutics reports positive Phase 2 pancreatic cancer data
3M ago
8K
ACTU
Premium
The Fly
Actuate Therapeutics says Phase 2 study met primary endpoints
3M ago
ACTU
Premium
The Fly
Actuate announces results from Phase 1 portion of study of elraglusib
3M ago
ACTU
Premium
The Fly
Actuate Therapeutics announces publication of Phase II data for elraglusib
4M ago
ACTU
Premium
Company Announcements
Actuate Therapeutics Signs $100M Sales Agreement
5M ago
8K
ACTU
Premium
Ratings
Actuate Therapeutics: Strategic Advancements and Financial Outlook Drive Buy Rating
5M ago
ACTU
Premium
Ratings
Actuate Therapeutics Receives Buy Rating Amid Strategic Advancements and Financial Strengthening
7M ago
ACTU
Premium
The Fly
Actuate announces corporate update on regulatory path for elraglusib
7M ago
ACTU
Premium
Company Announcements
Actuate Therapeutics Announces Public Offering of Shares
7M ago
8K
ACTU
Premium
The Fly
Actuate prices 2.14M shares at $7.00 in underwritten public offering
7M ago
ACTU
Premium
The Fly
Actuate Therapeutics 2.142M share Secondary priced at $7.00
7M ago
ACTU
Premium
The Fly
Actuate Therapeutics announces common stock offering, no amount given
7M ago
ACTU
Premium
The Fly
Actuate Therapeutics files $250M mixed securities shelf
7M ago
ACTU
Premium
The Fly
Actuate Therapeutics initiated with a Buy at B. Riley
8M ago
ACTU
Premium
Ratings
Actuate Therapeutics, Inc.: Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating
8M ago
ACTU
Premium
The Fly
Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial
8M ago
ACTU
INCY
Premium
The Fly
Actuate Therapeutics files to sell 1.33M shares of common stock for holders
9M ago
ACTU
Premium
Ratings
Promising Clinical Developments and Valuation Support Buy Rating for Actuate Therapeutics
9M ago
ACTU
Premium
The Fly
Actuate Therapeutics announces end of Phase 1 portion of elraglusib study
9M ago
ACTU
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
